Finoriq research workspace
Azitra, Inc. (AZTR) SEC Filings & Filing Highlights
Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision. Review AZTR SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and topical live biotherapeutic products to treat skin diseases in the United States. The company develops ATR-04, a genetically modified strain of S. epidermidis that is in a Phase 1/2 clinical trial for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor targeted therapy; ATR-12, a genetically modified strain of S. epidermidis, which is in a Phase 1b/2a clinical trial for treating Netherton syndrome, a skin disease; and ATR-01, a genetically modified strain of S. epidermidis that expresses an engineered recombinant human filaggrin protein, which is in the IND-enabling phase for treating ichthyosis vulgaris, a skin disease. It has a joint development agreement with Bayer for the identification and characterization of S. epidermidis strains for topical formulations. Azitra, Inc. was incorporated in 2014 and is headquartered in Branford, Connecticut.
- Company
- Azitra, Inc. (AZTR)
- Ticker
- AZTR
- Market Cap
- $2.3M
- Latest Price
- $0.1444
- Industry
- Biotech & Pharma
Azitra, Inc. (AZTR) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for Azitra, Inc. (AZTR).
| Event | Form | Date |
|---|---|---|
| Azitra, Inc. CEO Issues Letter to Shareholders Detailing Strategic Reorientation Initiatives an...Azitra, Inc. CEO Issues Letter to Shareholders Detailing Strategic Reorientation Initiatives and Outlook for 2026 and Beyond | 8-K8.01 | 2026-06-17 |
| Azitra, Inc.: Shareholder voteOn June 15, 2026, the Company reconvened its 2026 annual meeting of stockholders (the “Annual Meeting”), which was initially convened and t... | 8-K5.07 | 2026-06-16 |
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal YearAmendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 8-K5.03 | 2026-06-16 |
| Azitra Announces Adjournment of 2026 Annual Meeting and Information for Reconvened MeetingAzitra Announces Adjournment of 2026 Annual Meeting and Information for Reconvened Meeting | 8-K8.01 | 2026-06-04 |
| Azitra Announces Intention to Adjourn Annual Meeting and Reconvene Annual MeetingAzitra Announces Intention to Adjourn Annual Meeting and Reconvene Annual Meeting | 8-K8.01 | 2026-05-27 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.